S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
NASDAQ:PODD

Insulet (PODD) Stock Price, News & Analysis

$169.25
+5.25 (+3.20%)
(As of 03/1/2024 08:52 PM ET)
Today's Range
$162.01
$170.61
50-Day Range
$163.60
$221.42
52-Week Range
$125.82
$335.91
Volume
1.50 million shs
Average Volume
952,295 shs
Market Capitalization
$11.84 billion
P/E Ratio
58.16
Dividend Yield
N/A
Price Target
$250.33

Insulet MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
47.9% Upside
$250.33 Price Target
Short Interest
Healthy
3.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
0.87mentions of Insulet in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$1.89 M Sold Last Quarter
Proj. Earnings Growth
28.71%
From $3.03 to $3.90 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

10th out of 947 stocks

Surgical & Medical Instruments Industry

1st out of 95 stocks


PODD stock logo

About Insulet Stock (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock Price History

PODD Stock News Headlines

Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
Stocks that are trading heavily or have substantial price changes on Friday: Sprouts, Block rise; Booking Holdings, Insulet fall
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Barclays Cuts Insulet (NASDAQ:PODD) Price Target to $213.00
Insulet (NASDAQ:PODD) Shares Down 2.6% After Analyst Downgrade
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Barclays Sticks to Its Hold Rating for Insulet (PODD)
Insulet (NASDAQ:PODD) Shares Gap Down After Analyst Downgrade
Insulet (NASDAQ:PODD) PT Lowered to $230.00
Insulet Full Year 2023 Earnings: Beats Expectations
Analyst Scoreboard: 5 Ratings For Insulet
Q4 2023 Insulet Corp Earnings Call
DexCom- A Winner in Diabetes Management
Insulet is about to announce its earnings — here's what to expect
Insulet Corporation
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/04/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,600
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$250.33
High Stock Price Target
$350.00
Low Stock Price Target
$184.00
Potential Upside/Downside
+47.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
16 Analysts

Profitability

Net Income
$206.30 million
Pretax Margin
12.65%

Debt

Sales & Book Value

Annual Sales
$1.70 billion
Cash Flow
$3.79 per share
Book Value
$10.48 per share

Miscellaneous

Free Float
69,297,000
Market Cap
$11.84 billion
Optionable
Optionable
Beta
0.99

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives















PODD Stock Analysis - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price target for 2024?

16 brokers have issued 12-month price targets for Insulet's stock. Their PODD share price targets range from $184.00 to $350.00. On average, they expect the company's share price to reach $250.33 in the next year. This suggests a possible upside of 47.9% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2024?

Insulet's stock was trading at $216.98 on January 1st, 2024. Since then, PODD stock has decreased by 22.0% and is now trading at $169.25.
View the best growth stocks for 2024 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PODD earnings forecast
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings results on Thursday, February, 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. The medical instruments supplier earned $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a trailing twelve-month return on equity of 32.19% and a net margin of 12.16%. The firm's revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $419.0 million-$429.7 million, compared to the consensus revenue estimate of $442.5 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (13.57%), Vanguard Group Inc. (11.50%), Capital World Investors (3.17%), Clearbridge Investments LLC (1.90%), Baillie Gifford & Co. (1.74%) and Norges Bank (1.50%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PODD) was last updated on 3/4/2024 by MarketBeat.com Staff